Grant of Options

RNS Number : 2516N
N4 Pharma PLC
18 May 2020
 

18 May 2020

 

N4 Pharma plc

("N4 Pharma", the "Company" or the "Group")

 

Grant of Options

 

N4 Pharma Plc (AIM: N4P), the specialist pharmaceutical company developing Nuvec®, a novel delivery system for cancer treatments and vaccines, announces the Company has today granted 1,434,286 options (the "Options") over ordinary shares of 0.4 pence in the Company ("Ordinary Shares") to certain Directors of the Company. These Options have been granted pursuant to the Company's Unapproved Share Option Scheme, as follows:

 

 

Director

Number of Options granted

Existing options over Ordinary Shares held

Total Options over Ordinary Shares held following grant

David Templeton Executive Director

717,143

717,143

1,434,286

Luke Cairns

Non-Executive Director

717,143

1,392,445

2,109,588

 

The Options have an exercise price of 4.8 pence per Option, being the closing mid-market price of an Ordinary Share on 15 May 2020, the business day prior to the grant. The Options can be exercised from three years from the grant date and up to the tenth anniversary of the grant date, provided that the individual remains an employee of the Company. Following the grant of the Options, the Company has options in issue over a total of 8,396,513 Ordinary Shares, representing 8.28 per cent. of the Company's current issued share capital, or 5.52 per cent. of the Company's issued share capital as enlarged by the placing announced on 13 May 2020.  

The FCA notifications, made in accordance with the requirements of the EU Market Abuse Regulation, are appended below.

Enquiries:

 

N4 Pharma Plc

Nigel Theobald, CEO

 

 

Via Scott PR

Allenby Capital Limited

James Reeve/Asha Chotai 

Tel: +44(0)203 328 5656

Scott PR

Georgia Smith

 

Tel: +44(0)1477 539 539

 

About N4 Pharma

 

N4 Pharma is a specialist pharmaceutical company developing a novel delivery system for cancer and vaccine treatments using its unique silica nanoparticle delivery system called Nuvec®.

 

N4 Pharma's business model is to partner with companies developing novel antigens for cancer and vaccine treatments to use Nuvec® as the delivery vehicle to get their antigen into cells to express the protein needed for the required immunity. As these products progress through pre clinical and clinical programs, N4 Pharma will seek to receive up front payments, milestone payments and ultimately royalty payments once products reach the market.

 

Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them. 

 

1

Details of the person discharging managerial responsibilities / person closely associated

a)

Name

David Templeton

 

2

Reason for the notification

a)

Position/status

Executive Director

b)

 

Initial notification /Amendment

Initial notification

3

 

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

N4 Pharma plc

b)

LEI

213800I841D2RKMFK955

4

 

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

 

Description of the financial instrument, type of instrument

 

Identification code

Options over Ordinary Shares of 0.4p each 

 

 

 

Identification code (ISIN) for N4 Pharma plc ordinary shares: GB00BYW8QM32

 

b)

Nature of the transaction

Issue of options over ordinary shares of 0.4p each

 

 

c)

Price(s) and volume(s)

 Price(s)

Volume(s)

4.8p exercise price

 

717,143

 

d)

Aggregated information

- Aggregated volume

- Price

 

n/a

e)

Date of the transaction

18 May 2020

f)

Place of the transaction

Outside a trading venue

 

1

Details of the person discharging managerial responsibilities / person closely associated

a)

Name

Luke Cairns

 

2

Reason for the notification

a)

Position/status

Non-Executive Director

b)

 

Initial notification /Amendment

Initial notification

3

 

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

N4 Pharma plc

b)

LEI

213800I841D2RKMFK955

4

 

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

 

Description of the financial instrument, type of instrument

 

Identification code

Options over Ordinary Shares of 0.4p each 

 

 

 

Identification code (ISIN) for N4 Pharma plc ordinary shares: GB00BYW8QM32

 

b)

Nature of the transaction

Issue of options over ordinary shares of 0.4p each

 

 

c)

Price(s) and volume(s)

 Price(s)

Volume(s)

4.8p exercise price

 

717,143

 

d)

Aggregated information

- Aggregated volume

- Price

 

n/a

e)

Date of the transaction

18 May 2020

f)

Place of the transaction

Outside a trading venue

 

 


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
DSHAPMATMTTBBMM

Companies

N4 Pharma (N4P)
UK 100

Latest directors dealings